CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting
CareDx announced the presentation of over 50 abstracts and 16 oral presentations at the ISHLT 2026 Annual Meeting, highlighting data supporting the clinical utility of its HeartCare and AlloSure Lung testing platforms. Key findings from the SHORE and ALAMO studies demonstrate the value of non-invasive molecular testing for early detection of rejection and longitudinal risk assessment, with SHORE data also linking molecular testing strategies to lower surveillance costs.
Key figures
- Oral presentations
- 16
- Abstracts presented
- 50
- Shore study centers
- 67
- Shore study patients
- 2700
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.